CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
तुलना करने के लिए मीट्रिक्स | CVAC | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCVACपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −2.3x | −3.0x | −0.5x | |
PEG अनुपात | −0.14 | −0.02 | 0.00 | |
क़ीमत/बुक | 1.7x | 1.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 9.6x | 4.9x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 118.1% | 53.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.2% | 9.6% | अनलॉक करें |